References
- DaPrada M, Zurcher G, Wuthricht I, Haefely W. On tyramine, food, beverages, and the reversible MAO inhibitor moclobemide. J Neural Transm 1988; 26(Suppl)31–56
- Golbe L I. Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmacol 1988; 11(5)387–400
- Heinonen E H, Rinne U K. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand 1989; 126: 103–111
- Bodkin J A, Amsterdam J D. Transdermal selegiline in major depression: a double‐blind, placebo‐controlled, parallel‐group study in outpatients. Am J Psychiatry 2002; 159(11)1869–1875
- Amsterdam J D. A double‐blind, placebo‐controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64(2)208–214
- Mann J J, Aarons S F, Wilner P J, Keilp J G, Sweeney J A, Pearlstein T, Frances A J, Kocsis J H, Brown R P. A controlled study of the antidepressant efficacy and side effects of (‐)‐deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989; 46(1)45–50
- McGrath P J, Stewart J W, Harrison W, Wager S, Nunes E N, Quitkin F M. A placebo‐controlled trial of l‐deprenyl in atypical depression. Psychopharmacol Bull 1989; 25(1)63–67
- Sunderland T, Cohen R M, Molchan S, Lawlor B A, Mellow A M, Newhouse P A, Tariot P N, Mueller E A, Murphy D L. High‐dose Selegiline in treatment‐resistant older depressive patients. Arch Gen Psychiatry 1994; 51(8)607–615
- Mawhinney M, Cole D, Azzaro A J. Daily transdermal administration of selegiline to guinea pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003; 55(1)27–34
- Wecker L, Goodhead M L, Azzaro A J, Pacheco M A. The Selegiline Transdermal System (STS): Targeted Effects on Monoamine Oxidases in the Brain. Presented at: American College of Neuropsychopharmacology Annual Meeting, San JuanPuerto Rico, December, 2000
- Hostynek J J, Magee P S. Performance of a SAR–QSAR model predictive of human ACD. In vitro Mol Toxicol 1999; 12(3)203–211
- Andersen K E, Maibach H I. Guinea pig sensitization assays. an overview. Curr Probl Dermatol 1985; 14: 263–290
- Pauporte M, Azzaro A J, Moonsammy G, Maibach H I. Selegiline transdermal system (STS): assessments of dermal safety in man. J Toxicol, Cutan Ocul Toxicol 2004; 23(3)179–187